192 related articles for article (PubMed ID: 26977006)
1. Update on Biomarkers in Development of Anti-angiogenic Drugs in Gastric Cancer.
Jia S; Cai J
Anticancer Res; 2016 Mar; 36(3):1111-8. PubMed ID: 26977006
[TBL] [Abstract][Full Text] [Related]
2. Controlling angiogenesis in gastric cancer: A systematic review of anti-angiogenic trials.
Shan F; Miao R; Xue K; Li Z; Li Z; Bu Z; Wu A; Zhang L; Wu X; Zong X; Wang X; Li S; Ji X; Jia Z; Li Z; Ji J
Cancer Lett; 2016 Oct; 380(2):598-607. PubMed ID: 26724681
[TBL] [Abstract][Full Text] [Related]
3. Predictive biomarkers for targeted and cytotoxic agents in gastric cancer for personalized medicine.
Wang S; Yuan L
Biosci Trends; 2016 Jul; 10(3):171-80. PubMed ID: 27251446
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.
Van Cutsem E; de Haas S; Kang YK; Ohtsu A; Tebbutt NC; Ming Xu J; Peng Yong W; Langer B; Delmar P; Scherer SJ; Shah MA
J Clin Oncol; 2012 Jun; 30(17):2119-27. PubMed ID: 22565005
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer.
Nienhüser H; Schmidt T
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29295534
[TBL] [Abstract][Full Text] [Related]
6. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
Jary M; Borg C; Bouché O; Kim S; André T; Bennouna J
Bull Cancer; 2015 Sep; 102(9):758-71. PubMed ID: 26232849
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.
Roviello G; Petrioli R; Marano L; Polom K; Marrelli D; Perrella A; Roviello F
Gastric Cancer; 2016 Jan; 19(1):31-41. PubMed ID: 26329368
[TBL] [Abstract][Full Text] [Related]
9. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
Marty M; Pivot X
Eur J Cancer; 2008 May; 44(7):912-20. PubMed ID: 18396037
[TBL] [Abstract][Full Text] [Related]
10. Emergence of potential biomarkers of response to anti-angiogenic anti-tumour agents.
Michael A; Relph K; Pandha H
Int J Cancer; 2010 Sep; 127(6):1251-8. PubMed ID: 20473879
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcome of anti-angiogenesis through VEGF-pathway in the management of gastric cancer: a systematic review of phase II and III clinical trials.
Mawalla B; Yuan X; Luo X; Chalya PL
BMC Res Notes; 2018 Jan; 11(1):21. PubMed ID: 29329598
[TBL] [Abstract][Full Text] [Related]
12. Molecularly targeted therapies in advanced gastric cancer.
Janjigian YY; Shah MA
Minerva Gastroenterol Dietol; 2011 Mar; 57(1):75-88. PubMed ID: 21372772
[TBL] [Abstract][Full Text] [Related]
13. Apatinib for the treatment of gastric cancer.
Geng R; Li J
Expert Opin Pharmacother; 2015 Jan; 16(1):117-22. PubMed ID: 25420417
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant and neoadjuvant therapy for gastric cancer.
Kelsen DP
Semin Oncol; 1996 Jun; 23(3):379-89. PubMed ID: 8658222
[TBL] [Abstract][Full Text] [Related]
15. Current status of targeted therapies in advanced gastric cancer.
De Vita F; Giuliani F; Silvestris N; Rossetti S; Pizzolorusso A; Santabarbara G; Galizia G; Colucci G; Ciardiello F; Orditura M
Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S29-34. PubMed ID: 22443228
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma.
Kolev Y; Uetake H; Iida S; Ishikawa T; Kawano T; Sugihara K
Ann Surg Oncol; 2007 Oct; 14(10):2738-47. PubMed ID: 17687613
[TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenic therapies for gastric cancer.
Hironaka S
Asia Pac J Clin Oncol; 2019 Aug; 15(4):208-217. PubMed ID: 31111678
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers in tumor angiogenesis and anti-angiogenic therapy.
Pircher A; Hilbe W; Heidegger I; Drevs J; Tichelli A; Medinger M
Int J Mol Sci; 2011; 12(10):7077-99. PubMed ID: 22072937
[TBL] [Abstract][Full Text] [Related]
19. Drug sensitivity testing platforms for gastric cancer diagnostics.
Lau V; Wong AL; Ng C; Mok Y; Lakshmanan M; Yan B
J Clin Pathol; 2016 Feb; 69(2):93-6. PubMed ID: 26567318
[TBL] [Abstract][Full Text] [Related]
20. Current advances in targeted therapies for metastatic gastric cancer: improving patient care.
Aguiar PN; Muniz TP; Miranda RR; Tadokoro H; Forones NM; Monteiro ID; Castelo-Branco P; Janjigian YY; De Mello RA
Future Oncol; 2016 Mar; 12(6):839-54. PubMed ID: 26838766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
